



May 10, 2018

News Release

MSD K.K.
Kyorin Holdings, Inc.

MSD and Kyorin Sign Agreement to Acquires Exclusive Distribution Rights for Therapeutic Agent for Allergic Rhinitis, NASONEX® Nasal

MSD K.K. (Head office: Chiyoda-ku, Tokyo, President: Jannie Oosthuizen, “MSD”), through its affiliate, and Kyorin Pharmaceutical Co.,Ltd. (“Kyorin”), a wholly owned subsidiary of Kyorin Holdings, Inc. (Head office: Chiyoda-ku, Tokyo, President: Minoru Hogawa), have signed an agreement according to which it will acquire the exclusive distribution rights in Japan to NASONEX® Nasal 50 µg of a therapeutic agent for allergic rhinitis that is manufactured and distributed by MSD.

NASONEX® has been approved and marketed in about 130 countries and regions as a therapeutic agent for seasonal allergic rhinitis and perennial allergic rhinitis. In 2008, MSD initiated the marketing of the agent in Japan, and MSD and Kyorin Pharmaceutical commenced joint promotion in November 2016. With this agreement, Kyorin Pharmaceutical will commence the solo marketing of the agent in Japan on August 1, 2018. MSD will continue to approve the manufacture and marketing of NASONEX®

MSD continues accelerating its R&D of innovative medicines based on the latest science in areas , maximizing the opportunity of existing products.

Kyorin will enhance its product lineup in the focus areas (respiratory and otological) with this acquisition of the exclusive distribution rights to NASONEX®, with the aim of improving its presence in this area.

Contact	
MSD K.K. Communications Kitanomaru Square, 1-13-12, Kudan-Kita Chiyoda-ku, Tokyo 102-8667 Tel: 03-6272-1001 Fax: 03-6238-9136	Kyorin Holdings, Inc. President's Office Corporate Communication 6, Kanda Surugadai 4-chome, Chiyoda-ku, Tokyo 101-8311 Tel: 03-3525-4707 Fax: 03-3525-4777